Trends in the Cath Lab: FFR Emerging as Stenting Gatekeeper
Clinical advancements in the cardiac catheterization lab most often occur in fits and starts, rarely in smooth progressions. Momentous developments like the percutaneous transluminal coronary angioplasty catheter, the bare metal stent, and then the drug-eluting stent shook both the profession and the industry. More recently, measurement of fractional flow reserve, a unique tool that assesses the severity of a coronary artery blockage by comparing blood flow at the distal and proximal ends of the lesion, is being utilized in greater numbers by interventional cardiologists as a combined refinement and development that shows great promise for both improving patient outcomes and lowering cost, all with few known negative consequences.
FFR is a unique tool that assesses the severity of a coronary artery blockage by comparing blood flow at the distal and proximal ends of the lesion.
by Curt Werner
Clinical advancements in the cardiac catheterization lab most often occur in fits and starts, rarely in smooth progressions. Momentous developments like the percutaneous transluminal coronary angioplasty (PTCA) catheter, the bare metal stent, and then the drug-eluting stent truly shook both the profession and the industry. Refinements usually follow
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.
Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.
